NASDAQ:QTNT Quotient Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Quotient Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.66 +0.01 (+0.18 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$5.55Now: $5.66▼$5.8450-Day Range$4.38MA: $5.99▼$8.2452-Week Range$2.39Now: $5.66▼$10.38Volume3.23 million shsAverage Volume849,728 shsMarket Capitalization$456.44 millionP/E RatioN/ADividend YieldN/ABeta2.4 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingQuotient has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.50, Quotient has a forecasted upside of 138.5% from its current price of $5.66.Amount of Analyst CoverageQuotient has only been the subject of 1 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesQuotient has received 293 “outperform” votes. (Add your “outperform” vote.)Underperform VotesQuotient has received 311 “underperform” votes. (Add your “underperform” vote.)Community SentimentQuotient has received 51.49% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Quotient and other stocks. Vote “Outperform” if you believe QTNT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe QTNT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldQuotient does not currently pay a dividend.Dividend GrowthQuotient does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Quotient insiders have bought more of their company's stock than they have sold. Specifically, they have bought $12,374,997.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 12.30% of the stock of Quotient is held by insiders.Percentage Held by Institutions77.64% of the stock of Quotient is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Quotient are expected to grow in the coming year, from ($1.27) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Quotient is -4.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quotient is -4.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.11 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:QTNT Previous Symbol CUSIPN/A CIK1596946 Webwww.quotientbd.com Phone011-41-22-716-9800Debt Debt-to-Equity Ratio9.74 Current Ratio4.54 Quick Ratio3.77Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$32.66 million Price / Sales13.98 Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / Book-80.86Profitability EPS (Most Recent Fiscal Year)($1.44) Net Income$-102,770,000.00 Net Margins-313.16% Return on EquityN/A Return on Assets-49.12%Miscellaneous EmployeesN/A Outstanding Shares80,643,000Market Cap$456.44 million Next Earnings Date11/2/2020 (Estimated) OptionableOptionable $5.66 +0.01 (+0.18 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive QTNT News and Ratings via Email Sign-up to receive the latest news and ratings for QTNT and its competitors with MarketBeat's FREE daily newsletter. Quotient (NASDAQ:QTNT) Frequently Asked Questions How has Quotient's stock been impacted by Coronavirus (COVID-19)? Quotient's stock was trading at $4.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, QTNT stock has increased by 22.0% and is now trading at $5.66. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Quotient? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quotient in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Quotient. When is Quotient's next earnings date? Quotient is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020. View our earnings forecast for Quotient. How were Quotient's earnings last quarter? Quotient Ltd (NASDAQ:QTNT) announced its quarterly earnings results on Monday, August, 3rd. The company reported ($0.32) EPS for the quarter, beating the Zacks' consensus estimate of ($0.33) by $0.01. The business had revenue of $8.92 million for the quarter, compared to analysts' expectations of $8.50 million. View Quotient's earnings history. What guidance has Quotient issued on next quarter's earnings? Quotient updated its FY 2021 Pre-Market earnings guidance on Monday, August, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $32-34 million, compared to the consensus revenue estimate of $36 million. What price target have analysts set for QTNT? 1 Wall Street analysts have issued 1 year target prices for Quotient's shares. Their forecasts range from $13.50 to $13.50. On average, they anticipate Quotient's stock price to reach $13.50 in the next year. This suggests a possible upside of 138.5% from the stock's current price. View analysts' price targets for Quotient. Who are some of Quotient's key competitors? Some companies that are related to Quotient include Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Heska (HSKA), Lantheus (LNTH), Meridian Bioscience (VIVO), Celldex Therapeutics (CLDX), Oxford Immunotec Global (OXFD), Aspira Women's Health (AWH), Vermillion (VRML), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Biomerica (BMRA), Trinity Biotech (TRIB), ImmuCell (ICCC) and Achieve Life Sciences (ACHV). View all competitors. What other stocks do shareholders of Quotient own? Based on aggregate information from My MarketBeat watchlists, some companies that other Quotient investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Verastem (VSTM), Gilead Sciences (GILD), SCYNEXIS (SCYX), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Novavax (NVAX), Micron Technology (MU) and Ocular Therapeutix (OCUL). Who are Quotient's key executives? Quotient's management team includes the following people: Mr. Franz Walt, CEO & Director (Age 60)Mr. Jeremy Stackawitz, Pres (Age 44)Mr. Edward Farrell, Pres (Age 49)Mr. Christopher J. Lindop, Chief Financial Officer (Age 61)Mr. John Allan, Corp. Sr. VP & CTO What is Quotient's stock symbol? Quotient trades on the NASDAQ under the ticker symbol "QTNT." Who are Quotient's major shareholders? Quotient's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Cormorant Asset Management LP (3.60%), TimesSquare Capital Management LLC (3.46%), Hudson Bay Capital Management LP (1.89%), Bellevue Group AG (0.74%), Gilder Gagnon Howe & Co. LLC (0.51%) and Tekla Capital Management LLC (0.51%). Company insiders that own Quotient stock include Edward Farrell, Frederick Hallsworth, Jeremy Stackawitz, Life Sciences Maste Perceptive, Perceptive Advisors Llc, Peter Buhler, Prondzynski Heino Von and Roland Boyd. View institutional ownership trends for Quotient. Which major investors are selling Quotient stock? QTNT stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Gilder Gagnon Howe & Co. LLC, TimesSquare Capital Management LLC, Two Sigma Advisers LP, DAVENPORT & Co LLC, Sei Investments Co., Swiss National Bank, and Arizona State Retirement System. Company insiders that have sold Quotient company stock in the last year include Edward Farrell, and Jeremy Stackawitz. View insider buying and selling activity for Quotient. Which major investors are buying Quotient stock? QTNT stock was acquired by a variety of institutional investors in the last quarter, including Hudson Bay Capital Management LP, Nuveen Asset Management LLC, Acuitas Investments LLC, Bellevue Group AG, Tekla Capital Management LLC, Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., and Roubaix Capital LLC. Company insiders that have bought Quotient stock in the last two years include Frederick Hallsworth, Life Sciences Maste Perceptive, Perceptive Advisors Llc, Peter Buhler, and Prondzynski Heino Von. View insider buying and selling activity for Quotient. How do I buy shares of Quotient? Shares of QTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Quotient's stock price today? One share of QTNT stock can currently be purchased for approximately $5.66. How big of a company is Quotient? Quotient has a market capitalization of $456.44 million and generates $32.66 million in revenue each year. The company earns $-102,770,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. What is Quotient's official website? The official website for Quotient is www.quotientbd.com. How can I contact Quotient? Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The company can be reached via phone at 011-41-22-716-9800. This page was last updated on 9/18/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
